Wells Fargo & Company Supernus Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 55,276 shares of SUPN stock, worth $2.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,276

Previous 55,245 0.06%

Holding current value

$2.01 Million

Previous $1.48 Million 16.66%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$25.77 - $35.16 $798 - $1,089	31 Added 0.06%	55,276 $1.72 Million
Q2 2024 Aug 13, 2024	BUY	$25.99 - $33.85 $167,479 - $218,129	6,444 Added 13.2%	55,245 $1.48 Million
Q1 2024 May 10, 2024	BUY	$27.11 - $35.17 $63,084 - $81,840	2,327 Added 5.01%	48,801 $1.66 Million
Q4 2023 Feb 09, 2024	SELL	$22.72 - $29.68 $12,473 - $16,294	-549 Reduced 1.17%	46,474 $1.34 Million
Q3 2023 Nov 13, 2023	SELL	$27.57 - $32.91 $407,236 - $486,113	-14,771 Reduced 23.9%	47,023 $1.3 Million
Q2 2023 Aug 15, 2023	BUY	$29.91 - $38.73 $301,223 - $390,049	10,071 Added 19.47%	61,794 $1.86 Million
Q1 2023 May 12, 2023	BUY	$34.93 - $42.03 $352,443 - $424,082	10,090 Added 24.24%	51,723 $1.87 Million
Q4 2022 Feb 13, 2023	SELL	$31.09 - $37.88 $243,279 - $296,411	-7,825 Reduced 15.82%	41,633 $1.49 Million
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $109,574 - $134,770	-3,806 Reduced 7.15%	49,458 $1.67 Million
Q2 2022 Aug 12, 2022	SELL	$25.33 - $34.25 $1.35 Million - $1.82 Million	-53,174 Reduced 49.96%	53,264 $1.54 Million
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $351,471 - $405,591	-12,328 Reduced 10.38%	106,438 $3.44 Million
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $623,413 - $808,995	-23,641 Reduced 16.6%	118,766 $3.46 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $407,147 - $542,921	17,296 Added 13.82%	142,407 $3.8 Million
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $2.33 Million - $2.89 Million	-87,065 Reduced 41.03%	125,111 $3.85 Million
Q1 2021 May 13, 2021	BUY	$24.15 - $31.45 $1.9 Million - $2.48 Million	78,857 Added 59.15%	212,176 $5.56 Million
Q4 2020 Feb 09, 2021	SELL	$17.7 - $25.81 $128,289 - $187,070	-7,248 Reduced 5.16%	133,319 $3.35 Million
Q3 2020 Nov 05, 2020	BUY	$20.2 - $25.05 $240,703 - $298,495	11,916 Added 9.26%	140,567 $2.93 Million
Q2 2020 Aug 13, 2020	BUY	$17.09 - $24.89 $164,439 - $239,491	9,622 Added 8.08%	128,651 $3.06 Million
Q1 2020 May 14, 2020	BUY	$14.45 - $24.69 $1.72 Million - $2.94 Million	119,029 New	119,029 $2.14 Million

Others Institutions Holding SUPN

# of Institutions

281

Shares Held

60.6M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.95B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Supernus Pharmaceuticals, Inc. Transaction History